As of 2025, 140 companies, including some in big pharma, were developing 160 NK cell strategies, including NK cell products (mostly allogeneic), NK cell engagers, and cytokines or other proteins to better unleash the function of NK cells (https://www.delveinsight.com/infographics/nk-cell-therapy-pipeline-insight).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Anders W.
Contact Anders W., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack